Capital Planning Advisors’s Pfizer PFE Stock Holding History

Capital Planning Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-14,584	Closed	-$422K	–	147
2024 Q3	$422K	Buy	14,584 +71	+0.5%	+$2.07K	0.06%	105
2024 Q2	$406K	Buy	14,513 +194	+1%	+$5.34K	0.07%	103
2024 Q1	$397K	Buy	14,319 +185	+1%	+$5.13K	0.07%	109
2023 Q4	$407K	Sell	14,134 -2,222	-14%	-$67.2K	0.08%	105
2023 Q3	$543K	Buy	16,356 +265	+2%	+$9.37K	0.11%	86
2023 Q2	$590K	Buy	16,091 +281	+2%	+$10.9K	0.12%	88
2023 Q1	$645K	Sell	15,810 -2,054	-11%	-$88.7K	0.14%	78
2022 Q4	$915K	Buy	17,864 +1,867	+12%	+$89.5K	0.22%	69
2022 Q3	$700K	Sell	15,997 -879	-5%	-$42.7K	0.19%	70
2022 Q2	$885K	Sell	16,876 -248	-1%	-$12.6K	0.23%	66
2022 Q1	$887K	Buy	17,124 +31	+0.2%	+$1.61K	0.19%	83
2021 Q4	$1.01M	Buy	17,093 +2,814	+20%	+$139K	0.19%	88
2021 Q3	$614K	Hold	14,279	–	–	0.13%	98
2021 Q2	$559K	Hold	14,279	–	–	0.11%	102
2021 Q1	$517K	Buy	14,279 +212	+2%	+$7.53K	0.12%	100
2020 Q4	$518K	Sell	14,067 -3,806	-21%	-$140K	0.13%	99
2020 Q3	$622K	Sell	17,873 -1,315	-7%	-$46.1K	0.17%	86
2020 Q2	$595K	Sell	19,188 -344	-2%	-$11.7K	0.18%	79
2020 Q1	$605K	Sell	19,532 -623	-3%	-$21.2K	0.23%	71
2019 Q4	$749K	Sell	20,155 -2,456	-11%	-$87.5K	0.2%	76
2019 Q3	$771K	Sell	22,611 -11,583	-34%	-$421K	0.22%	72
2019 Q2	$1.41M	Sell	34,194 -1,918	-5%	-$76.2K	0.41%	53
2019 Q1	$1.46M	Buy	36,112 +262	+0.7%	+$10.5K	0.44%	55
2018 Q4	$1.49M	Sell	35,850 -2,856	-7%	-$119K	0.54%	49
2018 Q3	$1.62M	Buy	38,706 +19,499	+102%	+$751K	0.52%	55
2018 Q2	$661K	Sell	19,207 -38,715	-67%	-$1.32M	0.3%	70
2018 Q1	$1.95M	Sell	57,922 -7,749	-12%	-$266K	0.69%	43
2017 Q4	$2.26M	Sell	65,671 -15,687	-19%	-$535K	0.79%	40
2017 Q3	$2.76M	Sell	81,358 -39,721	-33%	-$1.28M	1.08%	26
2017 Q2	$3.86M	Sell	121,079 -10,430	-8%	-$329K	1.71%	15
2017 Q1	$4.27M	Sell	131,509 -19,525	-13%	-$616K	2.11%	14
2016 Q4	$4.65M	Sell	151,034 -2,390	-2%	-$73K	2.48%	11
2016 Q3	$4.93M	Sell	153,424 -1,576	-1%	-$52.7K	2.63%	7
2016 Q2	$5.18M	Buy	155,000 +6,150	+4%	+$196K	2.88%	6
2016 Q1	$4.19M	Buy	148,850 +23,211	+18%	+$663K	2.02%	9
2015 Q4	$3.85M	Buy	125,639 +11,932	+10%	+$375K	2.24%	8
2015 Q3	$3.39M	Buy	113,707 +21,410	+23%	+$686K	2.23%	8
2015 Q2	$2.94M	Buy	92,297 +6,034	+7%	+$197K	1.72%	17
2015 Q1	$2.85M	Buy	86,263 +11,276	+15%	+$358K	1.98%	9
2014 Q4	$2.22M	Buy	+74,987	New	+$2.15M	1.92%	13

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital Planning Advisors's PFE Position: Q4 2024 in Review

Capital Planning Advisors sold out of Pfizer (PFE) in Q4 2024, closing a stake of 14,584 shares — an estimated $422K sold.

Capital Planning Advisors first reported a position in PFE in Q4 2014 and held it in 40 quarters. The position peaked at $5.18M in Q2 2016. 2,996 funds tracked by Wall St. Rank hold PFE as of Q4 2024.

Capital Planning Advisors reported no remaining Pfizer position as of Q4 2024 after selling out during the quarter.
Capital Planning Advisors sold 14,584 Pfizer shares in Q4 2024, an estimated $422K.
Capital Planning Advisors first reported a position in Pfizer in Q4 2014 and held it in 40 quarters.
Capital Planning Advisors's Pfizer position peaked at $5.18M in Q2 2016.
2,996 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.

Based on Capital Planning Advisors's 13F filing for Q4 2024, filed 17 Jan 2025.